Zynex (ZYXI) Projected to Post Earnings on Wednesday

Zynex (NASDAQ:ZYXI) is expected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Zynex to post earnings of $0.09 per share and revenue of $53.65 million for the quarter.

Zynex Price Performance

Shares of NASDAQ:ZYXI opened at $7.66 on Wednesday. The business has a 50-day moving average of $8.00 and a two-hundred day moving average of $8.06. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. Zynex has a fifty-two week low of $7.15 and a fifty-two week high of $13.77. The stock has a market capitalization of $243.97 million, a P/E ratio of 51.07 and a beta of 0.54.

Insider Buying and Selling at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $7.68, for a total value of $76,800.00. Following the sale, the chief financial officer now owns 19,738 shares of the company’s stock, valued at $151,587.84. The trade was a 33.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 30,000 shares of company stock valued at $236,400 in the last quarter. Corporate insiders own 52.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Zynex in a report on Friday, December 6th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.